Table 3.

Treatment emergent adverse events associated with L-DOPA. Items 32–33 on the Unified Parkinson’s Disease Rating Scale assess the presence or absence of motor side effects. Below, the total number of study subjects (N) and proportion of the sample (%) experiencing specific side effects are listed. All side effects experienced by at least one study subject at any time point are listed.

Variable	Week 1			Week 2			Week 3
Unified Parkinson’s Disease Rating Scale	Mean	SD	p vs. W0	Mean	ES vs. W0	p vs. W0	Mean	ES vs. W0	p vs. W0
Item 32	0.18	0.58	0.17	0.18	0.18	0.17	0.0	0.0	0.32
Item 33	0.09	0.38	0.09	0.09	0.09	0.09	0.0	0.0	0.32
Treatment Emergent Side Effect Scale	n	%		n	%		n	%
Nausea	7	19.4		6	17.1		3	9.1
Insomnia	3	8.3		2	5.7		1	3.0
Headache	1	2.8		1	2.9		2	6.1
Drowsiness	0	0.0		1	2.9		1	3.0
Dystonia	0	0.0		1	2.9		0	0
Akathisia	1	2.8		0	0		0	0
Dry mouth	0	0.0		0	0		1	3.0
Dizziness	0	0.0		0	0		1	3.0